There are currently 2868 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effect of a Dietary Supplement Rich in Nitric Oxide in Patients Diagnosed With Primary Ciliary Dyskinesia.
NCT04489472
Recruiting
The purpose of this study is to determine the effect of a dietary supplement rich in nitric oxide (NO) on nasal nitric oxide and fractional exhaled nitric oxide (FeNO),on ciliary beat frequency assessed by high-speed digital video microscopy and on lung function assessed by spirometry in normal patients and patients with Primary ciliary dyskinesia (PCD).
Gender:
ALL
Ages:
Between 4 years and 99 years
Trial Updated:
05/10/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Primary Ciliary Dyskinesia
Register for Updates
Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease
NCT04005976
Recruiting
The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Aortic Aneurysm, Aortic Dissection, Aortic Diseases
Register for Updates
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
NCT02610179
Recruiting
The goal of this prospective study is to determine whether there is superiority of 10 Twizzlers to the 50 gram glucola beverage for screening for GDM in a population based study.
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
05/09/2023
Locations: Ben Taub General Hospital, Houston, Texas
Conditions: Gestational Diabetes Mellitus
Register for Updates
COVID-19 Outcome Prediction Algorithm
NCT05471011
Recruiting
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: Michael E. DeBakey VA Medical Center, Houston, Texas
Conditions: COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
NCT05338073
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Register for Updates
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
NCT05769075
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2023
Locations: Oncology Consultants, Houston, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
BIOlogic Augmented Repair of Complex Anal Fistula Using Acellular Matrix and/or Autologous Platelet-rich Plasma
NCT05805449
Recruiting
The purpose of this study is to compare the clinical effectiveness of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix (UBM) to usual surgical care alone to prevent fistula recurrence or improve HRQoL, to compare the effects of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix on early postoperative pain and fecal continence and to ass... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Anal Fistula
Register for Updates
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05503355
Recruiting
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML, Adult
Register for Updates
HR-EGG in Medically Refractory Gastroparesis
NCT05789511
Recruiting
The goal of this observational study is to utilize a novel high resolution electrogastrography device to gauge if identification of gastric dysarrythmias can reliably identify patients that will respond to or will require definitive pyloric interventions such as a G-POEM procedure in patients with medically refractory gastroparesis Aims: 1. Assess for the presence of gastric dysarrythmias in lung transplantation population as compared to alternative etiologies of gastroparesis 2. Assess if pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Gastroparesis, Lung Transplant; Complications
Register for Updates
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT05054296
Recruiting
This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with prostate cancer that has spread to other places in the body (metastatic) or has come back (recurrent) and does not response to treatment (refractory) and are receiving androgen deprivation therapy. Balancing treatment efficacy, drug side effects, and competing comorbidities with prostate cancer is essential. This trial is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Texas MD Anderson, Houston, Texas
Conditions: Merkel Cell Carcinoma
Register for Updates